Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
Holding ALNY?
Track your performance easily
ALNY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$141.98 - $287.55
Previous Close$273.15
Volume129.49K
Average Volume (3M)1.22M
Market Cap
$35.76B
Enterprise Value$33.75B
Total Cash (Recent Filing)$2.62B
Total Debt (Recent Filing)$1.30B
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Oct 24, 2024EPS Estimate
-$0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding128,380,513
10 Day Avg. Volume617,617
30 Day Avg. Volume1,220,141
Standard Deviation0.14
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-13657.50
Price to Sales (P/S)15.03
Price to Cash Flow (P/CF)71.00
P/FCF Ratio75.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.39
Enterprise Value/Gross Profit22.23
Enterprise Value/Ebitda327.69
Forecast
1Y Price Target
$305.59Price Target Upside9.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Alnylam Pharma News
Bulls Say, Bears Say
Bulls Say
Market OpportunityPositive feedback from key opinion leaders reinforces confidence in vutrisiran’s differentiated profile and the large commercial opportunity in ATTR-CM.
Revenue PotentialAmvuttra's peak sales estimate of ~$11.6B is considered conservative, indicating potential for higher revenue.
Treatment EfficacyVutrisiran treatment was associated with benefits versus placebo across multiple well-established clinical measures of disease progression, including 6-Minute Walk Test, Kansas City Cardiovascular Questionnaire, and NYHA Class.
Bears Say
Market ShareA high Amvuttra price (vs. stabilizers) in ATTR-CM may negatively impact Amvuttra market share, due to potential payer preference for lower-cost therapies.
Reimbursement And InsuranceTwo branded drugs could be challenging to get insurance reimbursed, making the loss of exclusivity of Pfizer’s tafamidis an important date to note.
Valuation And ExpectationsRemain hesitant to enter at these levels, as more avenues to downside than upside are seen, given euphorically high expectations.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $141.97 and its highest was $287.55 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Oct 24, 2024 which is in 35 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Aug 01, 2024. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$1.067 by $0.937.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -$0.91.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 128,380,510 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$0.13 in its last earnings report, beating expectations of -$1.067. Following the earnings report the stock price went up 13.118%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 919M.
---
Alnylam Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$305.59 (9.70% Upside)
$305.59 (9.70% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 133.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.94%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
17.85%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
ALNY Company Deck
---
ALNY Earnings Call
Q2 2024
0:00 / 0:00
---
ALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
---
ALNY Stock 12 Month Forecast
Average Price Target
$305.59
▲(9.70% Upside)
Best Analysts Covering ALNY
1 Year
1 Year Success Rate
18/22 ratings generated profit
1 Year Average Return
+23.72%
reiterated a buy rating 17 days ago
Copying Paul Matteis's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +23.72% per trade.
---